retatrutide and pregnancy Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v How to Inject Retatrutide: Complete

Patent expirations for semaglutide (2033) and tirzepatide (2035) will enable generic manufacturers to enter the market, likely reducing all GLP-1 prices by another 4060%

The solubility of the compound allows for preparation in various aqueous solutions for different experimental protocols

According to Lillys release, the trial met its primary endpoint: participants titrating up to the highest orforglipron dose lost 27.3 lb (12.4%) of body weight at 72 weeks versus about 0.9% weight loss with placebo

They have been practice-changing owing to their glycaemic, cardiovascular, renal and weight loss benefits, and decreases in all-cause mortality

The impact of oligofructose on stimulation of gut hormones, appetite regulation and adiposity